Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ: MRNA )

35.53 +1.80 (+5.34%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Uncover the latest developments among S&P500 stocks in today's session.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Thursday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So.
Via The Motley Fool
Moderna: A Generational Opportunity for Investors in 2025
Moderna had a weak quarter but reaffirmed guidance, expecting three new product approvals in 2025 and as many as ten more within three years. 
Via MarketBeat
Exposures COVID-19 Product Safety
Uncover the latest developments among S&P500 stocks in today's session.
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Will Moderna's Retained 2025 Outlook Bolster Its Depressed Shares?
The company came up with a mixed fourth-quarter report, but kept its outlook for 2025. 
Via Investor's Business Daily
Why Moderna (MRNA) Stock Is Up Today
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 financial results.... 
Via StockStory
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Analyst Confident In Moderna's Cancer Vaccine But Highlights Other Challenges
Moderna misses Q4 EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake challenges. 
Via Benzinga
Exposures COVID-19
Stay informed with the top movers within the S&P500 index on Tuesday.
Stay updated with the movements of the S&P500 index in the middle of the day on Tuesday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
This Moderna Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
Health Insurance ETFs in Focus as RFK Jr Takes Over HHS
Robert F. Kennedy Jr. has taken office as HHS secretary, which could impact the healthcare sector, including ETFs with exposure to insurers like UnitedHealth and Elevance Health. 
Via Benzinga
Topics ETFs
10 Worst Performing Large-Caps Last 12 Months
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
Which S&P500 stocks are the most active on Friday?
Explore the S&P500 index on Friday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest and driving market movements. 
Via Chartmill
Moderna (MRNA) Q4 2024 Earnings Call Transcript
MRNA earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks Head For Weekly Gains, US Treasury Yields Fall Below 4.5%: What's Driving Markets Friday?
Stocks are headed for weekly gains, with the Dow Jones dipping slightly and the S&P 500 and Nasdaq trading just above the flatline Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Discover which S&P500 stocks are making waves on Friday.
Let's have a look at what is happening on the US markets in the middle of the day on Friday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Moderna’s Q4 Losses Worse Than Feared, But Revenue Beat And Cost Cuts Boost Stock — Retail Sentiment Follows
CEO Stéphane Bancel said the company remains focused on driving sales and achieving up to 10 product approvals by 2027, as well as removing nearly $1 billion in costs by the end of this year. 
Via Stocktwits
Moderna's Q4 Loss Wider Than Expected
The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 vaccine sales. 
Via The Motley Fool
Exposures COVID-19
Which S&P500 stocks are moving before the opening bell on Friday?
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements. 
Via Chartmill
Applied Materials, Informatica, Clearwater Paper And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Moderna Struggles With Declining Q4 COVID Vaccine Sales, Stock Slides
Moderna reported a Q4 EPS loss of $2.91, missing estimates, with revenue down 66% YoY to $966 million. The company reaffirmed 2025 guidance and cost-cutting plans. 
Via Benzinga
Exposures COVID-19
Moderna’s (NASDAQ:MRNA) Q4 Earnings Results: Revenue In Line With Expectations But Full-Year Sales Guidance Misses Expectations Significantly
Biotechnology company Moderna (NASDAQ:MRNA) met Wall Street’s revenue expectations in Q4 CY2024, but sales fell by 65.6% year on year to $966 million. On the other hand, the company’s full-year revenue... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Dow Jumps Over 300 Points Following Recent Inflation Data; Investor Sentiment Improves, Fear & Greed Index Moves To 'Neutral' Zone
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Palo Alto Networks, Moderna And 3 Stocks To Watch Heading Into Friday
Via Benzinga
US Stocks Set For A Volatile Start: Analyst Dismisses Chances Of 20%+ S&P 500 Gain For Third Year In A Row, But Says 'Investors Should Be Optimistic'
U.S. stock futures traded close to the flatline on Friday after Tuesday's rally. Futures of all four benchmark indices were slightly lower. 
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Scheduled For February 14, 2025
Via Benzinga
Moderna Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Via Benzinga
Moderna Q4 Earnings Preview: COVID-19 Vaccine Sales, Bird Flu Vaccine Candidates On Watch
Moderna is set to release its fourth-quarter earnings on Friday before the opening bell. Here's a look at what to expect in the report: 
Via Benzinga
Exposures COVID-19
Robert F. Kennedy, Vaccine Skeptic, Confirmed As Trump's Secretary Of Health: Health Care Stocks To Watch
The U.S. Senate voted on Thursday to confirm President Donald Trump's nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human Services. 
Via Benzinga
Topics Government
Exposures Political
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.